Add BrightSurf on Google Email

Caltech scientists uncover structure of key protein in common HIV subgroup

Researchers have uncovered the three-dimensional structure of a key protein found on the surface of a specific HIV-1 subgroup, providing valuable insights for vaccine design. The discovery reveals unusual autoreactivity between an anti-HIV antibody and the CD4 receptor, raising questions about potential autoimmune responses.

SourceCalifornia Institute of Technology·JournalNature Structural & Molecular Biology·DateApr 2, 2010

Stem cell therapy to tackle HIV

A novel stem cell therapy has been developed to arm the immune system against HIV, potentially improving quality of life and life expectancy for those who have failed antiviral drugs. The therapy involves delivering antiviral DNA to patient immune cells, which can block viral gene production using RNA interference.

Predictors of loss of hepatitis B surface antigen in patients co-infected with HIV and HBV

A study analyzed factors associated with HBsAg loss in HIV-HBV co-infected patients. Higher baseline CD4 cell counts were linked to increased loss of HBsAg, suggesting effective T-cell response against HBV. The research contributes to understanding predictors of HBsAg loss and its implications for management.

SourceWorld Journal of Gastroenterology·JournalWorld Journal of Gastroenterology·DateMar 30, 2010

How to fortify the immunity of HIV patients

Researchers at Universite de Montreal and VGTI have discovered a new mechanism by which HIV infects immune cells, characterizing the role of two molecules PD-1 and IL-10 in this process. The study suggests that blocking these interactions may restore the immune response in HIV-infected patients.

SourceUniversity of Montreal·JournalNature Medicine·DateMar 7, 2010

Combined drug therapy to treat TB and HIV significantly improves survival

A new study published in the New England Journal of Medicine found that initiating antiretroviral therapy during tuberculosis treatment significantly reduces mortality rates for co-infected patients. The trial, which involved 642 patients, showed a 56% reduction in mortality rates compared to those who received sequential therapy.

SourceColumbia University's Mailman School of Public Health·JournalNew England Journal of Medicine·DateFeb 25, 2010

Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug

Researchers identified two compounds that bind to novel parts of the HIV protease enzyme, which could improve potency of existing treatments and combat drug-resistant strains. These findings open a new approach to drug design against HIV protease, targeting non-active sites that may help restore effectiveness against resistant superbugs.

SourceScripps Research Institute·JournalChemical Biology & Drug Design·DateFeb 3, 2010

Herpes medication does not reduce risk of HIV transmission, UW-led international study finds

A five-year international study found that acyclovir suppressive therapy did not reduce the risk of HIV transmission in couples where one partner had both HIV and HSV-2. The study revealed significant reductions in plasma HIV levels and genital ulcers, but no impact on HIV transmission.

SourceUniversity of Washington School of Medicine/UW Medicine·JournalNew England Journal of Medicine·DateJan 20, 2010

HIV: Positive lessons from home-based care

A Cochrane Systematic Review found that home-based nursing in HIV/AIDS patients significantly improves self-reported knowledge of HIV, awareness of medications, and self-reported adherence to medication programmes. Home-based care also had a positive impact on HIV stigma, worry, and physical functioning.

SourceWiley·JournalCochrane Database of Systematic Reviews·DateJan 19, 2010

Blood fats reduced in HIV patients who switch from lopinavir-ritonavir to raltegravir, but viral supression rate lower in raltegravir patients (SWITCHMRK trials)

A recent study found that HIV patients who switch from lopinavir-ritonavir to raltegravir experience a reduction in blood fat levels, but the rate of viral suppression is lower in the raltegravir group. The results suggest that clinicians need to consider individual patient factors when making treatment decisions.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJan 12, 2010

New ways to pressure HIV

Researchers found that unique reading frames in the HIV genome can induce immune responses, potentially leading to new ways to combat the virus. These findings may prove useful for developing more effective HIV vaccines.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·DateJan 11, 2010

Directly observed antiretroviral therapy offers no benefit over self-administered treatment for HIV patients

A meta-analysis of 10 studies involving 1862 HIV patients found no statistically significant difference between directly observed and self-administered antiretroviral therapy in promoting virological suppression. This suggests that directly observed therapy may not be necessary to support adherence in the general patient population.

SourceThe Lancet_DELETED·JournalThe Lancet·DateNov 30, 2009

Many pregnant women avoid HIV screening in Africa

A recent study found that only 60% of pregnant women in Eastern and Southern Africa were tested for HIV in 2007. The authors suggest that women may be avoiding testing due to opt-out policies or concerns about the stigma associated with HIV. This highlights the need for increased awareness and access to HIV screening in these regions.

SourceFaculty of 1000·JournalAIDS·DateNov 19, 2009

HIV vaccine failure probably caused by virus used, says new research

Researchers found that people who had previously built up immunity to the adenovirus used in the trial had a higher risk of infection with HIV after receiving the vaccine. The study suggests that other adenovirus-based vaccines, such as those for tuberculosis and malaria, may also be at risk due to the same immune system reaction.

SourceImperial College London·JournalProceedings of the National Academy of Sciences·DateNov 16, 2009

No-entry zones for AIDS virus

Researchers at German Cancer Research Center find that HIV virus rarely integrates into genes with high transcription activity. This discovery could lead to the development of specific AIDS drugs targeting these 'cold spots', potentially offering a new approach to combat the virus.

SourceHelmholtz Association·JournalAIDS·DateNov 12, 2009

Shape of things to come: Structure of HIV coat could lead to new drugs, says Pitt team

Researchers at the University of Pittsburgh School of Medicine have identified a functional importance seam in the HIV coat that could lead to new treatments for blocking HIV infection. The findings may allow scientists to rationally design therapeutic compounds that interfere with assembly and function of the protein.

Taking medicine for HIV proves hard to swallow for many people

Two University of Washington studies show that drinking alcohol doubles the risk of non-adherence to HIV medication. A third study found that peer support, electronic pagers, or both had no lasting impact on adherence rates. The challenges of adhering to life-long HIV treatment highlight the need for individualized comprehensive programs.

SourceUniversity of Washington·JournalJAIDS Journal of Acquired Immune Deficiency Syndromes·DateOct 22, 2009

Continuing racial differences in HIV prevalence in US

Research found racial differences in individual behaviors do not fully explain marked disparities in HIV infection prevalence. Social factors such as exposure to the virus through racially segregated mixing patterns and poverty contribute to these differences. The US response to the epidemic has failed to control the spread of HIV amon...

SourceElsevier Health Sciences·JournalAmerican Journal of Preventive Medicine·DateOct 6, 2009